Status:
This is the original version (as it was originally made). UK Statutory Instruments are not carried in their revised form on this site.
Article 3(i)
THE SCHEDULEENTRIES INSERTED IN SCHEDULE 1 TO THE PRINCIPAL ORDER
| Column 1 | Column 2 | Column 3 | Column 4 | Column 5 |
|---|
| Substance | Maximum strength | Route of administration, use or pharmaceutical form | Treatment limitations | Maximum quantity |
|---|
| Aloxiprin | (1) 620 mg
| (1) Non-effervescent tablets and capsules
| | (1) The quantity sold or supplied in one container or package shall not exceed 32
|
| | (2) All preparations other than non-effervescent tablets or capsules
|
| Diphenhydramine Hydrochloride | | All preparations except liquid-filled capsules |
| Hydrocyanic Acid |
| Ibuprofen Lysine | | Rheumatic and muscular pain, pain of non-serious arthritic conditions, backache, neuralgia, migraine, headache, dental pain, dysmenorrhoea, feverishness, symptoms of colds and influenza |
| | Internal | (a)In the case of a prolonged release preparation 600 mg (MD) 1,200 mg (MDD)
(b)in any other case 400 mg (MD) 1,200 mg (MDD)
|
| Levocabastine Hydrochloride | Equivalent of 0.05 per cent Levocabastine | (1) Nasal sprays
For the symptomatic treatment of seasonal allergic rhinitis
| | (1) Container or package containing not more than 10 ml of medicinal product
|
| | (2) Aqueous eye drops
For the symptomatic treatment of seasonal allergic conjunctivitis
| | (2) Container or package containing not more than 4 ml of medicinal product
|
| Nilutamide |
| Phytomenadione | | Any use except the prevention or treatment of haemorrhagic disorders |
| Strychnine Nitrate |
| Sulfabenzamide |
Back to top